Figure 3.
(A) α-synuclein oligomerization and toxicity in Parkinson’s disease (PD). HSP27 prevents α-synuclein misfolding and aggregation into amyloid fibrils. (B) HSP27 α-synuclein-binding sites: N-terminal region, C-terminal region, and α-crystallin domain (ACD). (C) HSP27 increased levels by L-DOPA treatment could promote cardioprotection in the heart.